Trial Profile
A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Doxorubicin; Paclitaxel
- Indications Endometrial cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms IXAMPLE2
- Sponsors Bristol-Myers Squibb
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 19 Jul 2019 As per European Clinical Trials Database record, trial is completed in UK (24 Feb 2014).
- 04 Mar 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov.